Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer With Bone Mets and Progressive Disease Following Prior CTX.
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Abituzumab (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004067).
- 23 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
- 06 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History